What Procto-Glyvenol Treats: Main Uses and Benefits

The combination of tribenoside and lidocaine is commonly used for the local management of symptomatic internal and external hemorrhoids, and may be part of symptomatic management for distressing acute symptoms associated with the condition. The therapeutic scope is associated with addressing both localized discomfort and associated tissue issues.

---

Symptom Management and Therapeutic Support

This preparation is generally used in situations involving certain distressing symptoms, primarily targeting acute, heightened sensory manifestations such as localized pain, severe perianal itching (pruritus), and a burning sensation. It is also applied across domains where additional symptomatic support is needed, particularly when hemorrhoids present with local swelling, edema, and inflammation. This range of use includes the primary indications of the preparation.

It is relevant for managing symptoms that interfere with daily comfort, and may assist with maintaining functional stability during difficult episodes. This topical option is also considered relevant in contexts involving symptomatic discomfort in certain patient groups, such as those in the postpartum period.

“The preparation may assist with easing the overall symptom load during an episode.”

---

Quick Fact: Relief for Anorectal Discomfort

The preparation is applied in scenarios where additional management of discomfort is required, and is relevant for easing the intensity of both sensory and tissue-based symptoms associated with hemorrhoidal disease.

Regulatory References

1. Summary of Product Characteristics

Who Can and Cannot Use Procto Glyvenol?

The eligibility for Procto Glyvenol is strictly defined by regulatory labeling concerning age, pre-existing conditions, and physiological status. The preparation is intended for adult use only.

---

Contraindications and Restricted Use

Category	Regulatory Status	Description
Absolute Contraindication	Must Not Use	Patients with known hypersensitivity or allergy to the active ingredients (Tribenoside, Lidocaine Hydrochloride), any excipients, or other amide-type local anesthetics.
Pediatric Population	Not Recommended	Should not be used in children or adolescents due to a lack of established clinical experience and safety data in this age group.
Pregnancy (1st Trimester)	Conditional Contraindication	Should not be used during the first three months of pregnancy unless specifically prescribed by a physician as absolutely necessary.
Severe Hepatic Impairment	Use with Caution	Requires medical consultation, as the preparation should be used with caution in patients with severely impaired liver function.
Lactation	Conditional Use	Requires medical consultation; a decision must be made between continuing treatment and discontinuing breastfeeding, as lidocaine may pass into breast milk.

---

Other Eligibility Requirements

Use is acceptable for adults and for pregnant women after the first trimester (conditional on proper dosage). A mandatory medical examination is required prior to use if anal bleeding or suspected blood in the stool is present.

Interactions with other medicines and products

The official regulatory profile for Procto-Glyvenol is highly restricted, largely due to the medicine’s topical administration and the explicit documentation that no formal drug interaction studies have been conducted. As a result, the regulatory labeling does not contain specific data concerning potential pharmacokinetic effects, such as those involving metabolic CYP enzymes or drug transporters.

Despite the lack of dedicated studies, regulatory sources advise specific caution regarding co-administration with two particular categories of medicinal products. This warning addresses a potential pharmacodynamic interaction related to the known systemic activity of the Lidocaine component.

Official Interaction Statements and Cautions

• Interaction-related Restriction: Caution is advised for patients concurrently taking beta-blockers or other antiarrhythmic drugs.
• Official Risk: The restriction is based on the potential for additive toxic effects, which may result in serious cardiac consequences, such as myocardial depression, as noted in the Summary of Product Characteristics.
• Data Absence: No mandatory timing-based administration rules or separation requirements are stipulated for this preparation.
• Substance Interactions: Official sources do not document specific interactions with food, alcohol, herbal products, or nutritional supplements.

This interaction profile is defined by the single pharmacodynamic caution related to Lidocaine, reflecting the limited scope of regulatory documentation for a topically administered combination product.

How Procto Glyvenol Works: Mechanism of Action

The pharmacological action of the combination is based on two complementary and distinct mechanisms that target nerve signaling and tissue physiology.

---

Direct Inhibition of Nerve Impulse Transmission

This domain is mediated by the Lidocaine component, which engages voltage-gated sodium channels ( VGSCs) on peripheral nerve membranes. By binding reversibly to these channels, the mechanism physically blocks the influx of sodium ions, which is required for nerve depolarization and the conduction of an action potential. This targeted blockade of the nociceptive signaling pathway rapidly results in a localized neuronal stabilization, interrupting the transmission of peripheral afferent nerve impulses.

---

Stabilization of Capillary Structure and Anti-Inflammatory Modulation

This mechanism is driven by the Tribenoside component, which modulates microvascular permeability and local inflammatory mediator activity. The component acts to stabilize capillary endothelial wall structure, reducing fluid and protein extravasation. Simultaneously, it modulates the release of key inflammatory mediators like histamine and bradykinin, which contributes to a decrease in interstitial fluid accumulation and dampens the local inflammatory cascade.

Administration Scope

The preparation is available for rectal and topical use as a suppository (400 mg Tribenoside, 40 mg Lidocaine) or a rectal cream (50 mg/ g Tribenoside, 20 mg/ g Lidocaine Hydrochloride). The approved administration route is exclusively non-oral; the medicine must not be swallowed. Standard adult dosing follows a dual-phase schedule.

Dosing Phase	Frequency and Unit	Duration Constraint
Acute/Initial Phase	Once per unit twice daily (morning and evening)	Self-treatment is limited to seven days.
Maintenance Phase	Once per unit once daily	Continue until symptoms are diminished.

The timing of administration is independent of meal times.

Procedural and Population-Specific Rules

Instructions require the affected area to be cleaned and dried before application, and hands must be washed thoroughly before and after use. For the rectal cream, a supplied applicator is used for internal application, while suppositories are inserted into the anus so they do not protrude.

The label defines specific use constraints for certain populations. The product is strictly intended for adult use; it is not suitable for pediatric administration. Furthermore, use is constrained in the first trimester of pregnancy; the suppository form must not be used during the first three months of pregnancy, but may be used from the fourth month onward. Dosing also requires caution in patients with severe liver function disorders.

Connection to the Overall Use Protocol

The guidelines establish a structured, two-part dosing protocol that transitions from an initial twice-daily frequency to a maintenance once-daily frequency, strictly applied via the topical/rectal route. This framework is governed by non-negotiable procedural steps, such as cleaning the area and handwashing, and adherence to specific population constraints, ensuring the application aligns with established protocols.

Research Evidence / Overview of Studies

The combination treatment of tribenoside and lidocaine (known commercially as Procto Glyvenol) has been evaluated in multiple clinical studies for the local management of hemorrhoidal disease.

Combination Component Activities

Studies focused on the individual components to understand the potential mechanisms. Research suggests:

• Tribenoside: Evaluated for its potential to affect vascular tone and permeability, which are factors associated with the swelling and inflammation of hemorrhoids. Preclinical models have investigated its role in supporting the integrity of blood vessel walls and tissues.
• Lidocaine: Studied primarily as a local anesthetic, where its function is to interrupt nerve signals in the area of application, a mechanism intended to provide localized relief from discomfort.

Clinical Findings

Clinical trials have examined the use of the combination treatment in patients with both internal and external hemorrhoids, typically focusing on low-grade disease where conservative topical management is indicated.

Research explored differences in subjective symptoms (such as pain, burning, and itching) and objective signs (such as bleeding and inflammation) when the combination was compared to its individual components or to other topical preparations, including some containing corticosteroids.

• Symptom Relief: Data from these studies reported changes in the severity of subjective symptoms, with some reviews noting the local anesthetic (lidocaine) was associated with rapid onset of relief for pain and itching.
• Specific Populations: Studies also specifically evaluated the tolerability of the combination in pregnant women (after the first trimester) and postpartum women with hemorrhoids, reporting data on both subjective and objective symptom improvement in these groups.

Safety and Tolerability

Safety was assessed across the trials. Commonly reported adverse events were generally local and mild, including burning sensation or itching at the site of application. Serious systemic side effects were rare, consistent with the minimal systemic absorption reported for tribenoside in studies.

Key Studies & References

1. TREATMENT OF HEMORRHOIDS WITH TRIBENOSIDE AND LIDOCAINE

Common questions about Procto Glyvenol (FAQ)

Q: What is the specific approved indication (what is it used to treat)?

Official product information states the preparation is intended for the local management of both external and internal hemorrhoids.

---

Q: What should I do if I miss a dose of Procto-Glyvenol?

If a dose is forgotten, regulatory documentation suggests skipping that missed dose. Official guidance indicates that a double dose should not be applied to make up for a missed dose.

---

Q: What are the storage conditions for the cream and suppositories?

Official labeling specifies that the medicine must be stored out of the sight and reach of children. It should be kept below either 30 C or 25 C, depending on the specific product label. This storage guidance applies to both the rectal cream and the suppositories.

---

Q: Can I use this medicine for more than seven days?

Regulatory information indicates that self-treatment for a new onset of symptoms must not last longer than seven days. If symptoms continue or worsen after this initial period, consulting with a healthcare professional is indicated before continued use. The official guidelines describe a maintenance phase that may continue until symptoms diminish, but any use beyond the initial period should be discussed with a healthcare provider.

---

Q: Can Procto-Glyvenol interact with any other medications I'm taking?

Caution is advised in the official product profile if other medications are being taken concurrently. Specifically, patients taking beta-blockers or other antiarrhythmic drugs should be cautious. This warning is based on the potential for additive toxic effects, including the risk of serious cardiac consequences such as myocardial depression (a weakening of the heart muscle).

How to Store and Dispose of Procto-Glyvenol

Official regulatory labeling dictates strict rules for the storage and disposal of Procto-Glyvenol (Tribenoside/Lidocaine HCl) to maintain product integrity and ensure public safety.

Storage Requirements

Condition	Regulatory Rule
Temperature	Store below 30 C (some labels specify below 25 C).
Protection	Keep in the original package to ensure protection from moisture.
Child Safety	Must be stored out of the sight and reach of children.
Stability	Do not use the product after the stated expiry date ( EXP).

Disposal Requirements

Unused or expired Procto-Glyvenol must not be thrown away via wastewater or household waste. The official instruction is to ask a pharmacist how to properly dispose of the medicine to protect the environment.